OC-AUTO® FIT

Improving colorectal cancer screening saves lives

Colorectal cancer (CRC) has the second-highest death rate among cancers. If detected at an early stage, 90% of all CRC deaths are preventable, but over 30% of adults ages 50-75 are not getting screened as recommended.1,2

Tier 1 recommendations support annual FIT screening for 45–75 year olds3,4,5

To improve patient outcomes for average-risk adults, the US Preventive Services Task Force, American College of Gastroenterology, and the US Multi-Society Task Force on Colorectal Cancer guidelines recommend3,4,5

Annual FIT

Colonoscopy every 10 years

Based on the new guidelines, nearly 100 million US adults should be screened annually.

Advancing CRC screening is critical. Choosing a CRC screening solution is simple

The only Tier 1, guideline-recommended FIT backed by proven clinical outcomes3,6

  • The #1 automated noninvasive CRC screening tool in the world7
  • Excellent sensitivity and specificity
  • Easier at-home screening for patients
  • Customizable programmatic services to help optimize screening
OC-Auto® FIT Product Image
US Preventative Services Task Force Logo

“The OC-Light and the OC FIT-CHEK® family of FITs have the best test performance characteristics (ie, highest sensitivity and specificity).”8

–US Preventive Services Task Force

American College of Gastroenterology Logo

“The fecal immunochemical test product [by Polymedco] is the FIT test with the best clinical evidence to support its use.”9

–Dr Douglas Rex, Past President of the American College of Gastroenterology (ACG)

The only FIT backed by proven clinical outcomes

Increase in patient compliance6

43.8%

Shown to improve up-to-date screening status

Reduction in annual CRC incidence6

25.5%

Reduction in cancer mortality6

52.4%

~90%

“Adherence to the screening program increased progressively over the years, reaching almost 90% of the target population.”10

FIT is more cost effective than other types of noninvasive colorectal screening tests11

Comparison chart of FIT and mt-SDNA tests showing cost per test and annual cost for all patients screened

*Multi-target stool DNA test.

Improved patient experience and ease of use makes annual FIT screening a reality

At-home collection

99.8%

of patients returned the collection device correctly12

Single-sample

Only requires milligrams of sample from one bowel movement

90%

of survey respondents reported that the automated test collection device was simple-to-very easy to use12

No-mess process

93%

of respondents that had previously performed the Guaiac test collection preferred the FIT test collection procedure (which is completely closed and without dietary restrictions)12

Download the brochure

See how easy screening can be with OC-AUTO FIT

Meet your CRC screening goals with solutions and support to optimize your screening program

  • In-service trainings, in person or remote
  • Patient and provider educational materials
  • Patient instructions in over 40 languages
  • Business reviews to assess impact
  • Mailing FIT directly to the patient’s home to help improve access to care

OC-Auto FIT

Excellent sensitivity and specificity get more of the right patients in for diagnostic procedures

Specificity for colorectal cancer (true negative) 94.9%13
Sensitivity for colorectal cancer (true positive) 73.8-84.513
Ranking: USMSTF Tier 13,5

OC-Auto Sensor io + Sensor Diana

OC-Auto Fit Sensor DIANA

Fully automated FIT analyzers designed with laboratories in mind

Increase productivity

Remove subjectivity of reading results

Update patient records automatically

OC-Auto Sensor io OC-Auto Sensor Diana
Detection of fecal occult blood in stool for colorectal cancer screening
Single samples with no dietary restrictions
15-day inoculated stability
# of tests per hour 88 280
Closed sampling bottle
Built-in sample bar code reader
Latex agglutination immunoassay
QC & calibration liquid ready -
Dimensions (width x depth x height) 14.2” x 22.1” x 16.7” 24.8” x 22” x 22”

Ordering information

Contact us

Connect with us

Fill out the form to submit your information.

References:

  1. Siegel RL, Wagle NS, Cercek A, Smith, RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233-254. doi:10.3322/caac.21772
  2. Data & Progress. National Colorectal Cancer Roundtable. May 10, 2023. Accessed July 11, 2023. https://nccrt.org/data-progress/
  3. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238
  4. Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. Am J Gastroenterol. 2021;116(3):458-479. doi:10.14309/ajg.000000000000122
  5. Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112(7):1016-1030. doi:10.1038/ ajg.2017.174
  6. Levin TR, Corley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology. 2018;155(5):1383-1391. doi:10.1053/j.gastro.2018.07.017
  7. Data on file with Polymedco, LLC.
  8. UPSTF. Public comment on draft recommendation statement and draft evidence review: screening for colorectal cancer. Accessed July 7, 2023 http://www.uspreventiveservicestaskforce.org/Announcements/News/Item/public-comment-on-draft-recommendation-statement-and-draftevidence-review-screening-for-colorectal-cancer
  9. NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals. Published June 13, 2013. Accessed July 7, 2023 https://www.jwatch.org/na31297/2013/06/13/finding-best-fit-colorectalcancer-screening
  10. Roselló S, Simón S, Cervantes A. Programmed colorectal cancer screening decreases incidence and mortality. Transl Gastroenterol Hepatol. 2019;4:84. doi:10.21037/tgh.2019.12.13.
  11. Allen CJ, Bloom N, Rothka M, et al. Comprehensive cost implications of commercially available noninvasive colorectal cancer screening modalities. J Am Coll Surg. 2023;10. doi:10.1097/XCS.0000000000000768
  12. Data on file internally with Polymedco, LLC. (2)
  13. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297. doi:10.1056/NEJMoa1311194